Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Avatar Builder | Contact Info | Update Email | Update Password | Leaderboards | Manage Favourite | Reputation | Reputation History | Subscriptions | Payment Info | Invoices | Favourites

Bullboard Post History

by Breakthorough

Order by:

IMVIF	RE:RE:RE:RE:RE:RE:Comparison with STR-002 More accurately. With the 10 still on treatment (I correct the distribution... December 5, 2020
IMVIF	RE:RE:RE:RE:RE:Comparison with STR-002 Of course. And the distribution of the 10 is 3 over 12 months, 6 over 6... December 5, 2020
IMVIF	RE:RE:RE:Comparison with STR-002 Thanks, qwerty22. I guess you wanted to say 1 (not 10) ongoing below six... December 4, 2020
IMVIF	RE:Comparison with STR-002 To be fair: 13% of patients still on treatment after a year. I guess 12month... December 4, 2020
IMVIF	Comparison with STR-002 Yesterday, Sutro Biopharma announced results of its ovarian cancer trial... December 4, 2020
IMVIF	The data for Pembro 1st BT designation Pembrolizumab, an antiPD-1 monoclonal antibody, received FDA's... December 3, 2020
IMVIF	RE:RE:RE:RE: Webcast What I got from the answers to JB (WF) and JP (HCW) is mainly: - They want to... December 3, 2020
IMVIF	RE:To measure tbe duration In the Trial appear as secondary outcomes DoR and TTP ("Time to... December 2, 2020
IMVIF	To measure tbe duration Will be interesting to see how they display the duration of "clinical... December 2, 2020
IMVIF	RE:RE:IMV Actual ORR is 26%. There were four patients left. There was the chance that... November 30, 2020
IMVIF	RE:RE:Fred Ors answer to D. Novak Here it is... "Sure, Jim, we, obviously, as we are planning to propose a... November 13, 2020
IMVIF	Fred Ors answer to D. Novak "Frederic Ors Thanks, David. Just as a reminder, the studies is done in... November 12, 2020
IMVIF	RE:-12%? Were the results that bad? Not so much volume though... November 12, 2020
IMVIF	RE:RE:The pembro trial may be... You are right. But it opens a questions. If pembro goes to first line (with... November 12, 2020
IMVIF	RE:RE:What is that study? This one says 10% A 2016 paper... May be the ongoing studies the paper mentions did not go so... November 12, 2020
IMVIF	The pembro trial may be... https://www.clinicaltrials.gov/ct2/show/NCT03990961?term=Pembrolizumab&... November 12, 2020
IMVIF	What is that study? This one says 10% Another PD-1 inhibitor, nivolumab, has shown impressive activity in classical... November 12, 2020
IMVIF	Ovarian data Dec-3; Basket Trial 1Q 2021 https://www.businesswire.com/news/home/20201112005180/en/ November 12, 2020

Featured News Links

Options Trading for Retiring: Key Strategies in Balancing Retirement Income

One Property, One Focus on Advancing this Gold Project in Ontario

Featured Company

Western Metallica Resources Corp. V.WMS

Western Metallica Resources Corp. is a Canada-based mineral exploration company with five mineral assets across Peru and ... view more »